- On **October 6, 2025**, NeuroSense Therapeutics Ltd. announced that its drug candidate, **PrimeC**, demonstrated **statistically significant reductions in multiple Alzheimer's disease (AD) biomarkers**.  **[1875091_0001213900-25-096310_ea0260357-6k_neuro.htm:0]** **[1875091_0001213900-25-096310_ea026035701ex99-1_neuro.htm:0]** 
- These positive findings were derived from plasma samples collected during the company's **Phase-2b PARADIGM study**.  **[1875091_0001213900-25-096310_ea026035701ex99-1_neuro.htm:0]** 
- PrimeC treatment significantly reduced several AD-associated microRNAs, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, which are implicated in neuroinflammation and neurodegenerative activity.  **[1875091_0001213900-25-096310_ea026035701ex99-1_neuro.htm:0]** 
- The company views these results as supporting PrimeC's potential as a **disease-modifying therapy** for AD by targeting central biological pathways.  **[1875091_0001213900-25-096310_ea026035701ex99-1_neuro.htm:0]** 
- NeuroSense plans to use these biomarker data to guide the design of a follow-on AD study, while also advancing PrimeC's Phase 3 readiness program for ALS.  **[1875091_0001213900-25-096310_ea026035701ex99-1_neuro.htm:0]**

NeuroSense Therapeutics Reports Positive Alzheimer's Biomarker Findings for PrimeC

- **Halberd Corporation** (OTC: HALB) has acquired **NeuroSense AI Corp.**, which is now an **89%-owned subsidiary**.  **[1875091_ecd35d54ac534c558c8cfbc2416c4420_0]** **[1875091_ecd35d54ac534c558c8cfbc2416c4420_2]** 
- NeuroSense AI is a **groundbreaking artificial intelligence platform** designed to revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment, utilizing **multi-modal behavioral signal fusion** powered by Claude AI technology.  **[1875091_ecd35d54ac534c558c8cfbc2416c4420_0]** 
- The platform aims to provide a **first-mover advantage** in the rapidly growing **$240 billion by 2030** global behavioral health market, with immediate applications in research, clinical settings, pharmaceutical development, and government/military.  **[1875091_ecd35d54ac534c558c8cfbc2416c4420_1]** 
- Halberd plans to implement this capability into upcoming **Phase 2 animal testing** at Mississippi State University and intends to pursue **FDA regulatory pathways** for the platform.  **[1875091_ecd35d54ac534c558c8cfbc2416c4420_0]** **[1875091_ecd35d54ac534c558c8cfbc2416c4420_1]**

Halberd Corporation Acquires NeuroSense AI Corp.

- NeuroSense Therapeutics Ltd. announced a new analysis of **18-month data** from its Phase 2b PARADIGM study of PrimeC in ALS.  **[1875091_0001213900-25-082945_ea0255499-6k_neurosense.htm:0]** 
- The analysis demonstrated a **statistically significant effect at 18 months (p=0.03)**, reflected in a **28% relative difference in ALS Functional Rating Scale-Revised (ALSFRS-R) decline** favoring patients who received PrimeC from the study's beginning.  **[1875091_0001213900-25-082945_ea0255499-6k_neurosense.htm:0]** 
- These results reinforce PrimeC’s potential as a **disease-modifying therapy for ALS**.  **[1875091_0001213900-25-082945_ea0255499-6k_neurosense.htm:0]**

NeuroSense Therapeutics (NRSN)